380 related articles for article (PubMed ID: 32470534)
1. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
Singh AP; Umbarkar P; Tousif S; Lal H
Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
3. Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
Hnatiuk AP; Bruyneel AAN; Tailor D; Pandrala M; Dheeraj A; Li W; Serrano R; Feyen DAM; Vu MM; Amatya P; Gupta S; Nakauchi Y; Morgado I; Wiebking V; Liao R; Porteus MH; Majeti R; Malhotra SV; Mercola M
Cancer Res; 2022 Aug; 82(15):2777-2791. PubMed ID: 35763671
[TBL] [Abstract][Full Text] [Related]
4. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
5. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
7. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib: a third-generation inhibitor for the treatment of CML.
Wehrle J; Pahl HL; von Bubnoff N
Recent Results Cancer Res; 2014; 201():99-107. PubMed ID: 24756787
[TBL] [Abstract][Full Text] [Related]
13. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Yang J; Surapaneni M; Schiffer CA
Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
[TBL] [Abstract][Full Text] [Related]
17. [French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].
Réa D; Messas E; Mirault T; Nicolini FE
Bull Cancer; 2022; 109(7-8):862-872. PubMed ID: 35725593
[TBL] [Abstract][Full Text] [Related]
18. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.
Casavecchia G; Galderisi M; Novo G; Gravina M; Santoro C; Agricola E; Capalbo S; Zicchino S; Cameli M; De Gennaro L; Righini FM; Monte I; Tocchetti CG; Brunetti ND; Cadeddu C; Mercuro G
Heart Fail Rev; 2020 May; 25(3):447-456. PubMed ID: 32026180
[TBL] [Abstract][Full Text] [Related]
19. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
Kumar V; Singh P; Gupta SK; Ali V; Verma M
Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
[TBL] [Abstract][Full Text] [Related]
20. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Deininger MW; Hodgson JG; Shah NP; Cortes JE; Kim DW; Nicolini FE; Talpaz M; Baccarani M; Müller MC; Li J; Parker WT; Lustgarten S; Clackson T; Haluska FG; Guilhot F; Kantarjian HM; Soverini S; Hochhaus A; Hughes TP; Rivera VM; Branford S
Blood; 2016 Feb; 127(6):703-12. PubMed ID: 26603839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]